Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting [Corrigendum]

This article refers to:

Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting

Senbel E, Tropé S, Herman-Demars H, et al. Patient Prefer Adherence. 2021;15:751–760.

Page 751, Abstract, Results section, the text “Switch to SC route increased the proportion of patients with remission or LDA from 22.8% to 52.9% and increased quality of life even in patients with unchanged MTX dose” should read “Switch to SC route increased the proportion of patients with remission or LDA from 22.2% to 52.3% and increased quality of life even in patients with unchanged MTX dose”.

The authors apologize for this error.